CClinicalTrials.gg
CompletedNCT03520621Updated May 11, 2018

The Role of Sulfur Amino Acids in Risk of Kwashiorkor

An observational study in Kwashiorkor, sponsored by Tufts University. Completed at 1 site in Congo, The Democratic Republic of the. Open to participants aged 36 Months to 59 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-11.

Sponsored by Tufts University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
360
Ages
36 Months to 59 Months
Sex
All
01

Study summary

This observational cross-sectional study is investigating if young children in populations with higher prevalence of kwashiorkor malnutrition have lower dietary sulfur amino acid intake than populations with lower prevalence of kwashiorkor, controlling for multiple potential confounding factors. Intake is estimated through diet recalls during interviews with a child's caregiver, analysis of urine samples and analysis of food samples for their amino acid profiles.

Read the detailed description

Kwashiorkor is one of two categorizations of severe acute malnutrition, but its etiology remains unclear. Although kwashiorkor is found only where diets are low in quality protein, comparisons of total dietary protein of individual children with and without kwashiorkor has been inconclusive. This study aims to compare amino acid profiles of the diets, not just total protein.

Evidence has shown that children with kwashiorkor consistently have very low circulating levels of sulfur amino acids (cysteine and methionine). Typical staple foods in regions with endemic kwashiorkor are generally poor in sulfur amino acids and the signs characterizing kwashiorkor can plausibly be explained by a shortage of sulfur amino acids.

In eastern Democratic Republic of the Congo, certain populations have chronically higher prevalence of kwashiorkor than neighboring populations with similar livelihoods, religion, environment, language and ethnicity. This study will compare these two populations to understand what differences between them may explain the difference in prevalence.

02

Conditions studied

  • Kwashiorkor

Browse trials for

Keywords

  • sulfur amino acid
03

In context

Kwashiorkor

44 studies on the registry are indexed under Kwashiorkor; 6 are open to participants now.

This study's enrollment of 360 is above the median of 82 across 11 observational studies indexed under Kwashiorkor.

Browse Kwashiorkor studies →

Lead sponsor

Tufts University is the lead sponsor of 225 studies on the registry; 24 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
36 Months to 59 Months
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study population, both groups, live within a 3 mile by 3 mile square in rural eastern Democratic Republic of the Congo.

Inclusion criteria

  • resident of the selected population
  • in the appropriate age range

Exclusion criteria

Exclusion Criteria:

  • caregiver reports the child has an illness that has required treatment for at least 6 months
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
360 participants (actual)
Patient registry
No

Groups and cohorts

  • High Prevalence Population

    Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is \>2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo

    Other: No intervention

  • Low Prevalence Population

    Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is \<2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo

    Other: No intervention

Interventions

  • OtherNo intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. Dietary sulfur amino acid

    mg of sulfur amino acid in the diet per kg of body weight

    Time frame: one measure at one time point within three weeks of registration

  2. dietary sulfur amino acid above or below WHO estimated average requirement (EAR)

    the total sulfur amino acid in the diet will be calculated from a diet recall this will be a bivariate measure, "1" if the SAA in the diet is above or "0" if below the WHO/FAO requirement for sulfur amino acid intake of 17mg of sulfur amino acids per kg of body weight per day

    Time frame: one measure at one time point within three weeks of registration

Secondary outcomes

  1. calories and protein in diet per kg of body weight

    intake of calories (kcal/kg body weight), digestibility adjusted protein - sum of (grams of protein per food item x digestibility of food item) per kg of body weight quality adjusted protein = digestibility adjusted protein in the diet x proportion of requirement of the limiting amino acid

    Time frame: one measure at one time point within three weeks of registration

  2. urinary sulfate

    sulfate excreted in the urine, normalized to creatinine

    Time frame: one measure at one time point within three weeks of registration

Other outcomes

  1. urinary thiocyanate

    thiocyanate excreted in the urine (ppm)

    Time frame: one measure at one time point within three weeks of registration

  2. socio-environmental factors (use of a latrine, shelter description, feeding habits, household demographics, health history)

    sanitation - does the child use a latrine, defecate in the woods/fields, defecate around the home shelter - materials used for the roof and walls, size of the home in square meters feeding habits - number of hot meals per day, number of feeding episodes per day household demographics - age and sex of all people who eat and sleep regularly at that homestead health history - illnesses in the past 30 days, previous diagnoses of malnutrition and type of malnutrition

    Time frame: one measure at one time point within three weeks of registration

  3. physical measurements of the subject's body size

    height to the nearest mm, weight to the nearest 100g, middle-upper arm circumference to the nearest mm, visual signs of kwashiorkor (edema, rough or darkened skin, friable lightened hair, distended abdomen, lethargy or irritability)

    Time frame: one measure at one time point within three weeks of registration

07

Study locations

1 site
  • Restore Hope for Africa
    Goma, North Kivu, Congo, The Democratic Republic of the
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03520621
Lead sponsor
Tufts University
Collaborators
World Concern, Action Contre la Faim, Rebuild Hope for Africa, Dignitas International
Responsible party
Sponsor
First posted
May 11, 2018
Start date
Jun 1, 2016
Primary completion
Aug 14, 2016
Completion
Aug 2, 2017
Last update
May 11, 2018

Study contacts

Daniel Maxwell, PhD
principal investigator · Tufts University, Friedman School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion